Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 5/20 | 0.44 |
| ▸ | CTSS | P25774 | 5/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | AKT1 | P31749 | 2/20 | 0.37 |
| ▸ | CTSL | P07711 | 2/20 | 0.37 |
| ▸ | CTSB | P07858 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 2/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4004775 | 1.00 | CTSK (0.44) | CTSKCTSSCA12CA1CA7 | |
| SCHEMBL7775510 | 0.84 | LMNA (0.39) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL2477747 | 0.84 | LMNA (0.39) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL2477749 | 0.84 | LMNA (0.39) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL4656265 | 0.78 | MMP1 (0.40) | CTSKCTSSSMN1; SMN2GAAKMT2A | |
| SCHEMBL4656263 | 0.78 | MMP1 (0.40) | CTSKCTSSSMN1; SMN2GAAKMT2A | |
| SCHEMBL2953752 | 0.76 | CA12 (0.47) | CTSKCTSSCA12CA1CA7 | |
| SCHEMBL1951583 | 0.76 | CA12 (0.47) | CTSKCTSSCA12CA1CA7 | |
| SCHEMBL1951666 | 0.76 | CA12 (0.47) | CTSKCTSSCA12CA1CA7 | |
| SCHEMBL5556773 | 0.75 | AKT1 (0.39) | CTSKCTSSCA12CA1CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1968924-B | Pyrrolidin-3-yl compounds as beta-secretase inhibitors for the treatment of Alzheimer's disease | MERCK & CO INC | 2011-08-03 | — | — | CN | disclosed |
| US-7714021-B2 | Pyrrolidin-3-yl compounds useful as beta-secretase inhibitors for the treatment of Alzheimer's disease | MERCK & CO., INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-20080287523-A1 | Pyrrolidin-3-Yl Compounds Useful as Beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease | MERCK SHARP & DOHME LLC | 2008-11-20 | — | — | US | disclosed |
| CN-1968924-A | Pyrrolidin-3-yl compounds as beta-secretase inhibitors for the treatment of Alzheimer's disease | MERCK & CO INC (US) | 2007-05-23 | — | — | CN | disclosed |
| CN-1177834-C | Dihydroxyhexanoic acid derivatives | �Ʒ� | 2004-12-01 | — | — | CN | disclosed |
| CN-1290255-A | Dihydroxyhexanoic acid derivatives | PFIZER PROD INC (US) | 2001-04-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287523-A1 | Pyrrolidin-3-Yl Compounds Useful as Beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease | BACE1, BACE2, APP | CTSK 163/4885CTSS 70/4885CA12 4279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.